Dynavax Technologies Corporation

DB:DYF1 Stock Report

Market Cap: €1.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Dynavax Technologies Management

Management criteria checks 2/4

Dynavax Technologies' CEO is Ryan Spencer, appointed in Dec 2019, has a tenure of 6.17 years. total yearly compensation is $8.21M, comprised of 10.2% salary and 89.8% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth €4.95M. The average tenure of the management team and the board of directors is 5 years and 4.3 years respectively.

Key information

Ryan Spencer

Chief executive officer

US$8.2m

Total compensation

CEO salary percentage10.17%
CEO tenure6.2yrs
CEO ownership0.3%
Management average tenure5yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ryan Spencer's remuneration changed compared to Dynavax Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$43m

Jun 30 2025n/an/a

-US$53m

Mar 31 2025n/an/a

-US$60m

Dec 31 2024US$8mUS$835k

US$27m

Sep 30 2024n/an/a

US$20m

Jun 30 2024n/an/a

US$17m

Mar 31 2024n/an/a

US$9m

Dec 31 2023US$6mUS$760k

-US$6m

Sep 30 2023n/an/a

US$61m

Jun 30 2023n/an/a

US$111m

Mar 31 2023n/an/a

US$236m

Dec 31 2022US$6mUS$695k

US$293m

Sep 30 2022n/an/a

US$320m

Jun 30 2022n/an/a

US$228m

Mar 31 2022n/an/a

US$104m

Dec 31 2021US$5mUS$600k

US$72m

Sep 30 2021n/an/a

-US$39m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$62m

Dec 31 2020US$2mUS$515k

-US$75m

Sep 30 2020n/an/a

-US$97m

Jun 30 2020n/an/a

-US$138m

Mar 31 2020n/an/a

-US$129m

Dec 31 2019US$3mUS$391k

-US$156m

Compensation vs Market: Ryan's total compensation ($USD8.21M) is above average for companies of similar size in the German market ($USD1.83M).

Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.


CEO

Ryan Spencer (46 yo)

6.2yrs
Tenure
US$8,210,775
Compensation

Mr. Ryan Spencer served as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024 to January 7, 2026. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporatio...


Leadership Team

NamePositionTenureCompensationOwnership
Ryan Spencer
CEO & Director6.2yrsUS$8.21m0.33%
€ 4.9m
Kelly MacDonald
Senior VP & CFO4.9yrsUS$2.63m0.053%
€ 784.5k
David Novack
Senior VP & COO12.9yrsUS$3.73m0.056%
€ 825.4k
John Slebir
Senior VP & General Counsel4.7yrsUS$2.85mno data
Robert Janssen
Chief Medical Officer and Senior VP of Clinical Development12.6yrsUS$2.28m0.068%
€ 1.0m
Joseph Metzinger
VP & Chief Accounting Officerless than a yearno datano data
Jeff Coon
Senior VP & Chief Human Resources Officer7.1yrsno datano data
Paul Cox
VP of Investor Relations & Corporate Communications3.1yrsno datano data
Donn Casale
Senior VP & Chief Commercial Officerno datano datano data
Dong Yu
Senior Vice President of Research5yrsno datano data
Eric Frings
VP, Site Head & MD for Dynavax GmbH5.1yrsno datano data
Meg Smith
Senior Vice President of Commercialless than a yearno datano data
5.0yrs
Average Tenure
60yo
Average Age

Experienced Management: DYF1's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ryan Spencer
CEO & Director6.2yrsUS$8.21m0.33%
€ 4.9m
Daniel Kisner
Independent Director15.6yrsUS$297.64k0.0013%
€ 19.6k
Francis Cano
Independent Director16.3yrsUS$285.64k0.018%
€ 271.5k
Robert Coffman
Member of Scientific Advisory Board3.1yrsUS$1.83mno data
Lauren Silvernail
Director1yrno datano data
Rino Rappuoli
Member of Scientific Advisory Board3.1yrsno datano data
Emilio Emini
Director1yrno datano data
Kathryn Edwards
Member of Scientific Advisory Board3.1yrsno datano data
Brent MacGregor
Independent Director5.6yrsUS$285.64kno data
Scott Myers
Independent Chairman of the Board4.3yrsUS$330.64k0.026%
€ 381.2k
Elaine Sun
Independent Director4.2yrsUS$290.64kno data
Peter Paradiso
Chairman of the Scientific Advisory Board & Independent Director5.4yrsUS$302.39k0.017%
€ 248.6k
4.3yrs
Average Tenure
72yo
Average Age

Experienced Board: DYF1's board of directors are considered experienced (4.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/09 07:47
End of Day Share Price 2026/02/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dynavax Technologies Corporation is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elemer PirosCantor Fitzgerald & Co.
Douglas BuchananCitizens JMP Securities, LLC
Jason ButlerCitizens JMP Securities, LLC